Hospital
Putnam Hospital Center
Putnam Hospital Center was paid $6.92M by Medicaid between Jan 2018 and Dec 2024, across 113 billing codes. Its largest line is 99283, emergency room visit (moderate) — 15% of everything it billed.
33Billing provider infoPUTNAM HOSPITAL CENTER
CARMEL, NY 10512
CARMEL, NY 10512
33aNPI1972557379assigned 05/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.92M
24GClaims131,815
24DCodes billed113
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#88 of 231
Median peer was paid$561K
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 76 | $375.79 | |
| 2019 | 8,200 | $350K | |
| 2020 | 19,517 | $957K | |
| 2021 | 26,535 | $1.37M | |
| 2022 | 26,515 | $1.42M | |
| 2023 | 28,253 | $1.58M | |
| 2024incomplete | 22,719 | $1.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 6,148 | 5,783 | $1.07M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 6,414 | 5,941 | $1.04M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 13% | 8,031 | 2,153 | $899K |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 2,688 | 2,503 | $741K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.9% | 4,108 | 3,879 | $682K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.0% | 1,542 | 1,498 | $415K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.0% | 1,290 | 1,252 | $343K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.5% | 1,534 | 1,489 | $242K |
| 80053 | Comprehensive metabolic panel | 3.1% | 9,197 | 8,128 | $216K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 3.0% | 944 | 928 | $210K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.5% | 4,975 | 1,395 | $171K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 813 | 741 | $161K |
101 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.2% | 3,500 | $155K |
| G0378 | Hospital observation service, per hour | 1.7% | 284 | $115K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,221 | $54K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 772 | $49K |
| 97161 | <1% | 329 | $46K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 168 | $44K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 291 | $23K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,607 | $21K |
| 86850 | <1% | 436 | $19K | |
| 86901 | <1% | 436 | $15K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,446 | $14K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 334 | $13K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 499 | $12K |
| 85610 | <1% | 2,983 | $11K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,049 | $11K |
| 83880 | <1% | 373 | $11K | |
| 86900 | <1% | 437 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 82 | $9K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,065 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 266 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 306 | $6K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 24 | $6K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,787 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,060 | $6K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 26 | $5K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 768 | $5K |
| 12001 | <1% | 13 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 34 | $5K |
| 99406 | <1% | 237 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,354 | $4K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 35 | $3K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,964 | $3K |
| 76641 | <1% | 120 | $3K | |
| 97162 | <1% | 14 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,909 | $2K |
| 93971 | <1% | 13 | $2K | |
| 84466 | <1% | 145 | $2K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 59 | $2K |
| 82728 | <1% | 117 | $1K | |
| 83735 | <1% | 2,297 | $1K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 245 | $960.05 |
| 81025 | <1% | 288 | $937.96 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 180 | $932.16 |
| 84484 | <1% | 2,718 | $867.26 | |
| 88304 | <1% | 12 | $832.48 | |
| 80320 | <1% | 1,051 | $665.90 | |
| 83540 | <1% | 144 | $642.41 | |
| 81001 | <1% | 2,536 | $637.79 | |
| 83605 | <1% | 1,047 | $521.51 | |
| 85730 | <1% | 1,144 | $455.57 | |
| 83690 | <1% | 2,221 | $402.52 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,382 | $400.07 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 13 | $366.97 |
| 84100 | <1% | 258 | $319.24 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,289 | $271.63 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,769 | $266.69 |
| 84703 | <1% | 2,111 | $262.81 | |
| 82607 | <1% | 29 | $262.08 | |
| 82746 | <1% | 27 | $251.03 | |
| 82948 | <1% | 1,200 | $242.21 | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $242.17 |
| 87400 | <1% | 1,857 | $232.10 | |
| 87468 | <1% | 12 | $183.54 | |
| 87484 | <1% | 12 | $183.54 | |
| 82947 | <1% | 603 | $176.14 | |
| 81003 | <1% | 1,746 | $167.28 | |
| 87040 | <1% | 436 | $147.66 | |
| 96376 | <1% | 125 | $144.22 | |
| 85379 | <1% | 309 | $139.02 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,436 | $134.89 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,735 | $130.43 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,635 | $118.36 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 406 | $102.80 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 713 | $100.87 |
| 87420 | <1% | 238 | $70.81 | |
| 85027 | <1% | 64 | $59.36 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,186 | $54.66 |
| 73130 | <1% | 12 | $42.26 | |
| 94761 | <1% | 157 | $39.61 | |
| 73630 | <1% | 12 | $36.67 | |
| 73610 | <1% | 14 | $32.83 | |
| 72100 | <1% | 14 | $29.70 | |
| 85007 | <1% | 49 | $28.46 | |
| 87430 | <1% | 345 | $27.62 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,101 | $27.21 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 68 | $19.76 |
| 87081 | <1% | 283 | $16.80 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 151 | $12.54 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,013 | $10.13 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 49 | $9.58 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 17 | $7.52 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 172 | $6.92 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 93 | $4.40 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 526 | $2.30 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 54 | $0.47 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 83 | $0.37 |
| A4649 | Surgical supply; miscellaneous | 0% | 43 | $0.00 |
| 86618 | 0% | 16 | $0.00 | |
| 80329 | 0% | 777 | $0.00 | |
| 87077 | 0% | 13 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMARCELLUS, DEBORAH (ASST VP PATIENT FINANCIAL SERVICES)